Khalifa Kush, the cannabis brand founded by recording artist Wiz Khalifa, today announced its international expansion into Europe. Starting in early 2025, Khalifa Kush will enter the German medical cannabis market through a multi-year partnership with Berlin-based Sanity Group and its medical cannabis brand, avaay Medical.
Beginning in January 2025, avaay will introduce two exclusive Khalifa Kush strains in the form of flower as a medical offering to German patients, with additional strain launches to follow throughout the year. Grown under GACP-certified conditions, these strains were specifically produced for the German market by British Columbia cultivator Miracle Valley and processed under EU-GMP standards. They will be available in more than 3,000 pharmacies throughout the country for licensed patients.
This move not only solidifies Khalifa Kush's foothold in the German market but also opens the door to further expansion across Europe, with neighboring countries such as Austria and Switzerland on the horizon.
